217 related articles for article (PubMed ID: 32444454)
21. Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model.
van der Heijden AA; Feenstra TL; Hoogenveen RT; Niessen LW; de Bruijne MC; Dekker JM; Baan CA; Nijpels G
Diabet Med; 2015 Dec; 32(12):1580-7. PubMed ID: 26010494
[TBL] [Abstract][Full Text] [Related]
22. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania.
Domeikienė A; Vaivadaitė J; Ivanauskienė R; Padaiga Ž
Medicina (Kaunas); 2014; 50(1):54-60. PubMed ID: 25060205
[TBL] [Abstract][Full Text] [Related]
23. The direct medical cost of type 2 diabetes.
Brandle M; Zhou H; Smith BR; Marriott D; Burke R; Tabaei BP; Brown MB; Herman WH
Diabetes Care; 2003 Aug; 26(8):2300-4. PubMed ID: 12882852
[TBL] [Abstract][Full Text] [Related]
24. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities.
Candrilli SD; Meyers JL; Boye K; Bae JP
J Diabetes Complications; 2015; 29(4):529-33. PubMed ID: 25660136
[TBL] [Abstract][Full Text] [Related]
25. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit.
Baxter M; Hudson R; Mahon J; Bartlett C; Samyshkin Y; Alexiou D; Hex N
Diabet Med; 2016 Nov; 33(11):1575-1581. PubMed ID: 26773733
[TBL] [Abstract][Full Text] [Related]
26. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes.
Choi SE; Sima C; Pandya A
Diabetes Care; 2020 Mar; 43(3):563-571. PubMed ID: 31882408
[TBL] [Abstract][Full Text] [Related]
27. Assessing the impact of complications on the costs of Type II diabetes.
Williams R; Van Gaal L; Lucioni C;
Diabetologia; 2002 Jul; 45(7):S13-7. PubMed ID: 12136406
[TBL] [Abstract][Full Text] [Related]
28. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
29. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
[TBL] [Abstract][Full Text] [Related]
30. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.
Alzaid A; Ladrón de Guevara P; Beillat M; Lehner Martin V; Atanasov P
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):785-798. PubMed ID: 32686530
[No Abstract] [Full Text] [Related]
31. Effect of a chronic disease management service for patients with diabetes on hospitalisation and acute care costs.
Rasekaba TM; Lim WK; Hutchinson AF
Aust Health Rev; 2012 May; 36(2):205-12. PubMed ID: 22624643
[TBL] [Abstract][Full Text] [Related]
32. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden.
Ringborg A; Yin DD; Martinell M; Stålhammar J; Lindgren P
Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):576-82. PubMed ID: 19491686
[TBL] [Abstract][Full Text] [Related]
33. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
Yu J; Shah BM; Ip EJ; Chan J
J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
[TBL] [Abstract][Full Text] [Related]
34. How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China?
Wang W; Fu CW; Pan CY; Chen W; Zhan S; Luan R; Tan A; Liu Z; Xu B
Value Health; 2009 Sep; 12(6):923-9. PubMed ID: 19824187
[TBL] [Abstract][Full Text] [Related]
35. Medical costs associated with type 2 diabetes complications and comorbidities.
Li R; Bilik D; Brown MB; Zhang P; Ettner SL; Ackermann RT; Crosson JC; Herman WH
Am J Manag Care; 2013 May; 19(5):421-30. PubMed ID: 23781894
[TBL] [Abstract][Full Text] [Related]
36. The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory.
Pagano E; De Rosa M; Rossi E; Cinconze E; Marchesini G; Miccoli R; Vaccaro O; Bonora E; Bruno G
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):944-50. PubMed ID: 27289165
[TBL] [Abstract][Full Text] [Related]
37. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
38. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
39. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.
Wake N; Hisashige A; Katayama T; Kishikawa H; Ohkubo Y; Sakai M; Araki E; Shichiri M
Diabetes Res Clin Pract; 2000 Jun; 48(3):201-10. PubMed ID: 10802159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
